Hirudin, a new therapeutic tool?
Research article published in Annals of hematology (1991)
Abstract
Hirudin is the most potent natural inhibitor of thrombin known to date. It is gaining popularity as an anticoagulant now that recombinant and synthesized forms are available. It is a monospecific and co-factor-independent thrombin inhibitor with otherwise inert pharmacological properties. Being a surprisingly weak immunogen, its administration has exhibited no side effects, particularly on platelets. Bleeding complications are not to be expected at therapeutic doses. Effective anticoagulatory doses can be easily predicted and laboratory control is no problem. Application of hirudin or derivatives thereof may be indicated for: prophylaxis and treatment of postoperative venous thrombosis and diffuse microthrombosis; prevention of arterial thrombosis, especially in cardiac surgery; enhancement of fibrinolytic therapy and/or angioplasty to prevent reocclusion; extracorporeal circulation; and plastic surgery. Hirudin may be a particularly useful alternative anticoagulatory agent in patients sensitized to heparin or in patients with hereditary or acquired antithrombin III deficiency. However, whether hirudin is really an effective therapeutic tool and whether it can replace heparin in certain clinical indications can be judged only after extended clinical experience has been accumulated.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Hirudin is the most potent natural inhibitor of thrombin known to date. It is gaining popularity as an anticoagulant now that recombinant and synthesized forms are available.
Why This Matters for Hirudotherapy
This review surveys hirudin — described in the abstract as the most potent natural inhibitor of thrombin known — and its pharmacological properties, including its monospecific, co-factor-independent mechanism, weak immunogenicity, and absence of platelet-related side effects, while outlining potential indications such as venous thrombosis prophylaxis, cardiac surgery, extracorporeal circulation, and use as a heparin alternative in sensitized patients or those with antithrombin III deficiency. The compound's name derives from the leech genus Hirudo, giving it a conceptual — though unstated in this abstract — connection to hirudotherapy; however, hirudin is discussed here solely as a recombinant or synthesized pharmaceutical agent, with no mention of leeches, leech saliva, or leech-derived sourcing. The review provides no new experimental or clinical data, and the authors explicitly caution that whether hirudin can truly replace heparin or serve as an effective therapeutic tool can only be judged after extended clinical experience.
Citation
Added to ASH library: March 18, 2026 · Site last updated: June 18, 2026